Literature DB >> 16651243

Which one is a risk factor for chemotherapy-induced febrile neutropenia in childhood solid tumors: early lymphopenia or monocytopenia?

Aynur Oguz1, Ceyda Karadeniz, Elvan Caglar Ckitak, Visal Cil.   

Abstract

Neutropenia is one of the undesirable effects of cancer chemotherapy, sometimes causing life-threatening events. The present study was conducted to identify the risk factors of neutropenia caused by chemotherapy. Between January 2001 and March 2004, a total of 77 children with 165 neutropenic attacks were enrolled in this study. Complete blood count was performed before chemotherapy and on days 1, 3, 5, 7, and 9 consecutively. The complete blood count results of the febrile neutropenia (FN) group were compared to those of the non-FN group. The incidence of FN was significantly higher in patients with ANC counts < or =0.5 x 10(9)/L on days 3, 5, and 7, lymphocyte counts < or =0.5 x 10(9)/L on days 7 and 9, < or =0.7 x 10(9)/L on days 5, 7, and 9, and with monocyte counts < or =0.15 x 10(9)/L on days 7 and 9, respectively. Further statistical analysis showed that lymphocyte count < or =0.7 x 10(9)/L on day 5, and monocyte count < or =0.15 x 10(9)/L on day 7 were independent risk factors for FN. The authors conclude that lymphocyte counts on the 5th day can be more a predictive factor than monocyte count.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16651243     DOI: 10.1080/08880010500457673

Source DB:  PubMed          Journal:  Pediatr Hematol Oncol        ISSN: 0888-0018            Impact factor:   1.969


  8 in total

1.  Monocytopenia; Induction by Vinorelbine, Cisplatin and Doxorubicin in Breast, Non-Small Cell Lung and Cervix Cancer Patients.

Authors:  Taha Nazir; Nida Taha; Azahrul Islam; Suraj Abraham; Adeel Mahmood; Mazhar Mustafa
Journal:  Int J Health Sci (Qassim)       Date:  2016-10

2.  Predictive value of monocytes and lymphocytes for short-term neutrophil changes in chemotherapy-induced severe neutropenia in solid tumors.

Authors:  Buhong Zheng; Zhiyu Huang; Yunxia Huang; Liang Hong; Jinluan Li; Junxin Wu
Journal:  Support Care Cancer       Date:  2019-06-25       Impact factor: 3.603

3.  Risk factors for febrile neutropenia in patients receiving docetaxel chemotherapy for castration-resistant prostate cancer.

Authors:  Masaki Shiota; Akira Yokomizo; Ario Takeuchi; Keijiro Kiyoshima; Junichi Inokuchi; Katsunori Tatsugami; Seiji Naito
Journal:  Support Care Cancer       Date:  2014-07-05       Impact factor: 3.603

4.  Lymphopenia as a prognostic factor for overall survival in advanced carcinomas, sarcomas, and lymphomas.

Authors:  Isabelle Ray-Coquard; Claire Cropet; Martine Van Glabbeke; Catherine Sebban; Axel Le Cesne; Ian Judson; Olivier Tredan; Jaap Verweij; Pierre Biron; Inthidar Labidi; Jean-Paul Guastalla; Thomas Bachelot; David Perol; Sylvie Chabaud; Pancras C W Hogendoorn; Philippe Cassier; Armelle Dufresne; Jean-Yves Blay
Journal:  Cancer Res       Date:  2009-06-23       Impact factor: 12.701

5.  Prognostic evaluation of febrile neutropenia in apparently stable adult cancer patients.

Authors:  A Carmona-Bayonas; J Gómez; E González-Billalabeitia; M Canteras; A Navarrete; M L Gonzálvez; V Vicente; F Ayala de la Peña
Journal:  Br J Cancer       Date:  2011-08-02       Impact factor: 7.640

6.  Evaluating the Prognostic Role of Monocytopenia in Chemotherapy-Induced Febrile Neutropenia Patients Treated with Granulocyte Colony-Stimulating Factor.

Authors:  Osama Alshari; Yazan O Al Zu'bi; Ahmed H Al Sharie; Farouk H Wafai; Abdelwahab J Aleshawi; Farah H Atawneh; Hasan A Obeidat; Majd N Daoud; Mohammad Z Khrais; Dima Albals; Faize Tubaishat
Journal:  Ther Clin Risk Manag       Date:  2021-09-07       Impact factor: 2.423

7.  Clinical predictive models for chemotherapy-induced febrile neutropenia in breast cancer patients: a validation study.

Authors:  Kai Chen; Xiaolan Zhang; Heran Deng; Liling Zhu; Fengxi Su; Weijuan Jia; Xiaogeng Deng
Journal:  PLoS One       Date:  2014-06-19       Impact factor: 3.240

8.  Pretreatment monocyte counts and neutrophil counts predict the risk for febrile neutropenia in patients undergoing TPF chemotherapy for head and neck squamous cell carcinoma.

Authors:  Marie Shimanuki; Yorihisa Imanishi; Yoichiro Sato; Nana Nakahara; Daisuke Totsuka; Emiri Sato; Sena Iguchi; Yasuo Sato; Keiko Soma; Yasutomo Araki; Seiji Shigetomi; Satoko Yoshida; Kosuke Uno; Yusuke Ogawa; Takehiro Tominaga; Yuichi Ikari; Junko Nagayama; Ayako Endo; Koshiro Miura; Takuya Tomioka; Hiroyuki Ozawa; Kaoru Ogawa
Journal:  Oncotarget       Date:  2018-04-10
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.